Evidence map›Paper›PMID 42533033›Full record

ArticleScientific reports2026

One-dimensional palladium MOF as VEGFR2 and colchicine binding inhibitors with potential anticancer and anti-inflammatory activities: synthesis and molecular investigation.

Heba K Abdelhakim, Safaa S Hassan, Khaled M Ismail

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Heba K AbdelhakimBiochemistry Division, Chemistry Department, Faculty of Science, Cairo University, Cairo, Egypt. Hebak@sci.cu.edu.eg.
Safaa S HassanChemistry Department, Faculty of Science, Cairo University, Giza, 12613, Egypt. hsafaa@sci.cu.edu.eg.
Khaled M IsmailChemistry Department, Faculty of Science, Cairo University, Giza, 12613, Egypt. kismail@sci.cu.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The innovation of a therapeutic agent with dual anti-inflammatory, anticancer and reversing the dynamic of microtubules like colchicine was crucial. VEGFR2 inhibition has been established as a therapeutic approach for managing cancer, the colchicine site, situated on ß-tubulin and α-tubulin was also considered in cancer development, and metastasis. Moreover, uncontrolled inflammation predisposes to pleiotropic effects leading to cancer development and promoting all stages of tumorigenesis. A polymeric state of a novel one-dimensional palladium-based metal-organic framework (1D Pd-MOF), resulting from the coordination of pyrazine with palladium nuclei to achieve the more pronounced effect of polynuclear characteristics of palladium compared to mononuclear compounds, was designed, synthesized, and screened for its anticancer activity against the A549 lung cancer cell line, with comparison to normal cells. The characterization was performed using different techniques and supported by DFT investigations. The 1D Pd MOF exhibited a potent cytotoxic effect, with an IC

Indexed as

Anti-Inflammatory AgentsAntineoplastic AgentsColchicinePalladiumVascular Endothelial Growth Factor Receptor-2A549 CellsApoptosisCell Line, TumorCell ProliferationHumansMolecular Docking SimulationTubulinAnti-Inflammatory AgentsAntineoplastic AgentsColchicineKDR protein, humanPalladiumTubulinVascular Endothelial Growth Factor Receptor-21D Pd MOFApoptotic genesDFT and dockingTubulin-interacting drugsVEGFR2 kinase

Identifiers

PMID42533033
PMCPMC13424319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.